DCT

1:26-cv-00873

Pfizer Inc v. MSN Pharma Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00873, D. Del., 07/16/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant MSN Pharmaceuticals Inc. is a Delaware corporation, and Defendant MSN Laboratories Pvt. Ltd. is subject to personal jurisdiction in the district through its business activities and those of its subsidiary.
  • Core Dispute: Plaintiff alleges that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of the cancer drug Inlyta® constitutes an act of infringement of a patent covering a specific crystalline form of the active pharmaceutical ingredient.
  • Technical Context: The technology at issue involves pharmaceutical polymorphs-distinct crystalline structures of the same chemical compound (axitinib)-which can have different physical properties affecting drug stability, manufacturability, and therapeutic performance.
  • Key Procedural History: This lawsuit was initiated under the Hatch-Waxman Act following Plaintiff's receipt of a notice letter, dated June 1, 2026, in which Defendant announced it had filed an ANDA with a Paragraph IV certification challenging the patent-in-suit.

Case Timeline

Date Event
2007-04-05 '140 Patent Priority Date
2012-01-27 FDA approves Pfizer's Inlyta® (axitinib) tablets
2014-07-29 U.S. Patent No. 8,791,140 is issued
2026-06-01 Defendant sends Paragraph IV certification notice letter
2026-07-16 Complaint for patent infringement is filed

II. Technology and Patent(s)-in-Suit Analysis

  • Patent Identification: U.S. Patent No. 8,791,140, "Crystalline Forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole Suitable for the Treatment of Abnormal Cell Growth in Mammals," issued July 29, 2014.

The Invention Explained

  • Problem Addressed: The background of the '140 Patent notes the general desirability in the pharmaceutical arts for drug compounds to exist in crystalline or amorphous forms that have physical properties-such as stability, filterability, and flow-amenable to reliable, large-scale manufacturing and formulation '140 Patent, col. 2:15-19 Different solid-state forms, or polymorphs, of the same drug can exhibit different properties, making the identification and selection of an optimal form a critical step in drug development '140 Patent, col. 2:39-49
  • The Patented Solution: The invention claims to solve this problem by identifying and characterizing specific, novel polymorphic forms of the anti-cancer compound axitinib ("Compound 1") '140 Patent, col. 2:20-30 These forms are uniquely defined by their analytical data, particularly their powder X-ray diffraction (PXRD) patterns, which act as fingerprints for the specific crystal lattice structure '140 Patent, col. 2:56-61 By isolating and patenting a specific form, the inventors sought to secure a version of the drug with consistent and advantageous properties.
  • Technical Importance: Controlling the polymorphic form of an active pharmaceutical ingredient is crucial for ensuring product consistency, quality, and performance, which are regulatory and commercial imperatives in the pharmaceutical industry.

Key Claims at a Glance

  • The complaint asserts infringement of claims 1-6 of the '140 Patent, with independent claim 1 being exemplary Compl. ¶35 Compl. ¶38
  • The essential elements of independent Claim 1 are:
    • A crystalline form of 6-[2-(methylcarbamoyl)phenyl-sulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole,
    • wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (20) of 6.0±0.1,
    • and further comprising at least one peak at diffraction angle (20) selected from 11.5±0.1, 21.0±0.1 and 26.9±0.1.
  • The complaint notes that Plaintiff reserves the right to assert additional claims Compl. ¶38

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is "MSN's ANDA Product," which is a generic version of Pfizer's Inlyta® (axitinib) tablets, in 1 mg and 5 mg strengths, for which MSN seeks FDA approval via ANDA No. 221598 Compl. ¶1 Compl. ¶2

Functionality and Market Context

  • The accused product is a generic equivalent intended to be substituted for Inlyta®, a drug approved for the treatment of advanced renal cell carcinoma Compl. ¶22 For the purposes of this litigation, its most relevant characteristic is the specific crystalline form of the active ingredient, axitinib. The complaint alleges, upon information and belief, that MSN's ANDA Product contains the crystalline form of axitinib covered by the claims of the '140 Patent Compl. ¶29 Compl. ¶36

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

  • Claim Chart Summary: The complaint provides a narrative infringement theory for claim 1. The core allegations are summarized below.

'140 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A crystalline form of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole... The complaint alleges that MSN's ANDA Product contains this specific crystalline form of axitinib. ¶36 col. 4:50-52
...wherein said crystalline form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (20) of 6.0±0.1... The crystalline form in MSN's ANDA Product is alleged to exhibit a powder X-ray diffraction pattern that includes this characteristic peak. ¶36 col. 4:53-56
...and further comprising at least one peak at diffraction angle (20) selected from 11.5±0.1, 21.0±0.1 and 26.9±0.1. The crystalline form in MSN's ANDA Product is alleged to exhibit a powder X-ray diffraction pattern that includes at least one of these additional characteristic peaks. ¶36 col. 4:53-62
  • Identified Points of Contention:
    • Infringement: The complaint makes a notable allegation that "In MSN's ANDA letter, MSN did not contest the infringement of claims 1-6 of the '140 patent on any basis other than the alleged invalidity and unenforceability of those claims" Compl. ¶37 If accurate, this suggests infringement may not be a primary point of dispute, and the case will instead center on the patent's validity.
    • Technical Questions: Assuming infringement were contested, the analysis would raise a key technical question: Does the powder X-ray diffraction data for the axitinib in MSN's ANDA Product show peaks that fall squarely within the claimed "±0.1" degree ranges? This would be a fact-intensive inquiry dependent on expert analysis of analytical data.

V. Key Claim Terms for Construction

  • The Term: "comprising a peak at diffraction angle (20) of [value]±0.1"
  • Context and Importance: This type of term is the linchpin of the claim, as it defines the patented polymorph by its "fingerprint" PXRD pattern. The precise scope of the numerical range, including the "±0.1" tolerance, is critical for determining whether a given sample infringes. Practitioners may focus on this term because even small variations in measurement could place an accused product inside or outside the claim scope.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party arguing for a slightly more flexible interpretation may point to the specification's general discussion of measurement variability, where it states that "one skilled in the art will appreciate that the peak positions (20) will show some variability, typically as much as 0.1 to 0.2 degrees" depending on the equipment and conditions '140 Patent, col. 12:33-36 This could be used to argue that the claim should not be read with inflexible literalness if minor experimental drift is observed.
    • Evidence for a Narrower Interpretation: A party arguing for a strict interpretation would assert that the claim explicitly and intentionally defines its own tolerance by reciting "±0.1". They may point to the detailed tables in the specification that distinguish numerous different polymorphs by their distinct peak locations (e.g., Form XXV, Form XVI, etc.), arguing that these precise numerical definitions are necessary to differentiate the claimed invention from other forms and are not merely suggestive '140 Patent, Tables 1, 4, 6

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, MSN will actively induce infringement by marketing and distributing its ANDA product with knowledge of the '140 Patent and with the specific intent to encourage infringing acts by others (e.g., physicians and patients using the product) Compl. ¶¶42-43 Compl. ¶45
  • Willful Infringement: Willfulness is alleged based on MSN's purported "full knowledge of the '140 patent" prior to the lawsuit, as evidenced by its Paragraph IV certification and notice letter Compl. ¶2 Compl. ¶46 The complaint alleges MSN acted "without a reasonable basis for believing that MSN would not be liable for infringing the '140 patent" Compl. ¶46

VII. Analyst's Conclusion: Key Questions for the Case

Based on the complaint, the litigation appears poised to center on the following issues:

  1. Validity as the Primary Battleground: Given the complaint's assertion that the defendant did not contest infringement in its pre-suit notice Compl. ¶37, a central question for the case will likely be one of patent validity. Will the defendant be able to prove, by clear and convincing evidence, that the asserted claims of the '140 Patent are invalid as being obvious or anticipated by the prior art?

  2. Confirmation of Infringement: While potentially not the main dispute, a necessary procedural question will be the evidentiary confirmation of infringement. Does the technical data concerning MSN's proposed generic product, as specified in its ANDA, conclusively demonstrate the presence of the crystalline form defined by the PXRD peaks in Claim 1?